drugset

drugset / Trial / NCT00198133

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

NCT00198133 ↗

Phase 2 Completed 27 enrolled Patrick Joseph Loehrer Sr.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study the efficacy of Alimta as a single agent in thymic cancers

Timeline

Start: 2005-01
Primary completion: 2006-12
Completion: 2012-05

Publications

Background Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, Loehrer PJ Sr. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. J Thorac Oncol. 2018 Dec;13(12):1940-1948. doi: 10.1016/j.jtho.2018.07.094. Epub 2018 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Indications